Key result
GM3 and other gangliosides are proposed as pathophysiological mediators in diabetic nephropathy, potentially compromising renal cell regeneration via VEGF receptor inactivation.
This review highlights the potential pathophysiological role of GM3 and other gangliosides in the development of diabetic nephropathy.
May identify novel targets in diabetic nephropathy; leaves open clinical translation pending validation.
Despite scientific advances, diabetic nephropathy remains both a therapeutical challenge, and one of the major diabetic complications. Chemical structure of gangliosides, the most complex of glycosphingolipids, is characterised by one or more sialic acids and carbohydrate groups linked to a ceramide structure. Their potential pathogenetic role in a number of disorders linked to diabetes mellitus has recently been conjectured, due to evidence of their negative modulation of the insulin-mediated signaling and general effects on key cell functions like proliferation, differentiation, apoptosis, cellular signaling and adhesion. Elevated levels of advanced glycation products (AGE) usually found in diabetic conditions seem to be responsible for increased concentration of a-series gangliosides in tissues, most notably GM3. GM3 was shown to compromise the renal pericyte and mesangial cell regeneration via the inactivation of VEGF receptor and the receptor-associated Akt signaling pathway. Likewise, the lipid raft theory opened a new research area for GM3 influence, since in the glycosynapse model glycosphingolipids have a key cell-to-cell communication unit with modulating capabilities on signaling receptors. The goal of this review is to provide insight into currently available theories on proposed mechanisms that mark the GM3 as a pathophysiological mediator in the development of diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Vuković et al. (2015) conducted a review in Diabetic nephropathy. GM3 and other gangliosides was evaluated. GM3 and other gangliosides are proposed as pathophysiological mediators in diabetic nephropathy, potentially compromising renal cell regeneration via VEGF receptor inactivation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: